[go: up one dir, main page]

WO2000071714A3 - Methods of reducing factor viii clearance and compositions therefor - Google Patents

Methods of reducing factor viii clearance and compositions therefor Download PDF

Info

Publication number
WO2000071714A3
WO2000071714A3 PCT/US2000/014111 US0014111W WO0071714A3 WO 2000071714 A3 WO2000071714 A3 WO 2000071714A3 US 0014111 W US0014111 W US 0014111W WO 0071714 A3 WO0071714 A3 WO 0071714A3
Authority
WO
WIPO (PCT)
Prior art keywords
factor viii
methods
provides
life
compositions therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/014111
Other languages
French (fr)
Other versions
WO2000071714A2 (en
Inventor
Evgueni L Saenko
Dudley K Strickland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American National Red Cross
Original Assignee
American National Red Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American National Red Cross filed Critical American National Red Cross
Priority to EP00937682A priority Critical patent/EP1183354A2/en
Priority to AU52822/00A priority patent/AU5282200A/en
Publication of WO2000071714A2 publication Critical patent/WO2000071714A2/en
Publication of WO2000071714A3 publication Critical patent/WO2000071714A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides methods of increasing the half-life of factor VIII. More specifically, the invention provides methods of increasing the half-life of factor VIII by substituting amino acids in the A2 domain or in the C2 domain of factor VIII or in both domains. It further provides factor VIII mutants produced by these methods. The invention also provides a method of using receptor-associated protein (RAP) to increase the half-life of factor VIII. The invention also provides polynucleotides encoding the mutant factor VIII, polynucleotides encoding RAP, and methods of treating hemophilia using the polypeptides and polynucleotides of the invention.
PCT/US2000/014111 1999-05-24 2000-05-24 Methods of reducing factor viii clearance and compositions therefor Ceased WO2000071714A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00937682A EP1183354A2 (en) 1999-05-24 2000-05-24 Methods of reducing factor viii clearance and compositions therefor
AU52822/00A AU5282200A (en) 1999-05-24 2000-05-24 Methods of reducing factor viii clearance and compositions therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13584799P 1999-05-24 1999-05-24
US60/135,847 1999-05-24

Publications (2)

Publication Number Publication Date
WO2000071714A2 WO2000071714A2 (en) 2000-11-30
WO2000071714A3 true WO2000071714A3 (en) 2001-01-18

Family

ID=22469983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/014111 Ceased WO2000071714A2 (en) 1999-05-24 2000-05-24 Methods of reducing factor viii clearance and compositions therefor

Country Status (3)

Country Link
EP (1) EP1183354A2 (en)
AU (1) AU5282200A (en)
WO (1) WO2000071714A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794493B2 (en) 2000-04-07 2004-09-21 Wisys Technology Foundation, Inc. Antithrombin H-helix mutants
JP2005518181A (en) 2001-01-12 2005-06-23 ジ・アメリカン・ナショナル・レッド・クロス Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
CA2450073C (en) * 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
EP1424344A1 (en) * 2002-11-29 2004-06-02 Aventis Behring Gesellschaft mit beschränkter Haftung Modified cDNA factor VIII and its derivates
EP1454916A1 (en) * 2002-11-29 2004-09-08 ZLB Behring GmbH Modified cDNA factor VIII and its derivatives
EP1454632A1 (en) * 2003-02-07 2004-09-08 Aventis Behring GmbH, Intellectual Property/Legal Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
SI2363414T1 (en) 2004-11-12 2022-09-30 Bayer Healthcare Llc Site-directed modification of FVIII
US20080227691A1 (en) * 2005-04-01 2008-09-18 Novo Nordisk Health Care Ag Blood Coagulation FVIII Analogues
CA2604299A1 (en) * 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation factor viii with enhanced stability and its derivates
US8877714B2 (en) * 2005-06-14 2014-11-04 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof
EP1945240B1 (en) * 2005-09-16 2016-12-28 Raptor Pharmaceutical Inc Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007338298B2 (en) * 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018827A1 (en) * 1994-01-07 1995-07-13 Novo Nordisk A/S Factor viii derivatives
US5650391A (en) * 1994-03-21 1997-07-22 Jewish Hospital Of St. Louis Methods and compositions for inhibition of hepatic clearance of tissue factor pathway inhibitor
EP0808901A2 (en) * 1996-05-24 1997-11-26 Immuno Ag Pharmaceutical preparation with factor VIII procoagulant activity and vWF-binding activity
WO2000027425A2 (en) * 1998-11-10 2000-05-18 Baxter Aktiengesellschaft Pharmaceutical preparation containing a receptor-antagonist for treating blood-clotting disorders
WO2000028021A1 (en) * 1998-11-10 2000-05-18 Baxter Aktiengesellschaft A factor viii-polypeptide with factor viii:c-activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018827A1 (en) * 1994-01-07 1995-07-13 Novo Nordisk A/S Factor viii derivatives
US5650391A (en) * 1994-03-21 1997-07-22 Jewish Hospital Of St. Louis Methods and compositions for inhibition of hepatic clearance of tissue factor pathway inhibitor
EP0808901A2 (en) * 1996-05-24 1997-11-26 Immuno Ag Pharmaceutical preparation with factor VIII procoagulant activity and vWF-binding activity
WO2000027425A2 (en) * 1998-11-10 2000-05-18 Baxter Aktiengesellschaft Pharmaceutical preparation containing a receptor-antagonist for treating blood-clotting disorders
WO2000028021A1 (en) * 1998-11-10 2000-05-18 Baxter Aktiengesellschaft A factor viii-polypeptide with factor viii:c-activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SAENKO E. L. ET AL.: "Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 53, 31 December 1999 (1999-12-31), pages 37685 - 37692, XP002152276, ISSN: 0021-9258 *
YAKHYAEV A. ET AL.: "Cellular uptake and degradation of the thrombin activated factor VIII fragments", BLOOD, vol. 90, no. 10, suppl. 1, 15 November 1997 (1997-11-15), pages 31A, XP000907187, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
AU5282200A (en) 2000-12-12
WO2000071714A2 (en) 2000-11-30
EP1183354A2 (en) 2002-03-06

Similar Documents

Publication Publication Date Title
WO2002060951A3 (en) Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
WO2000071714A3 (en) Methods of reducing factor viii clearance and compositions therefor
WO2005047322A3 (en) Factor viii compositions and methods
WO1995030750A8 (en) Lag-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody
CA2158750A1 (en) Monoclonal antibodies to casein kinase i polypeptides
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
WO2002103024A3 (en) Stabilized proteins with engineered disulfide bonds
AUPP051497A0 (en) Antimicrobial peptides
WO2003031598A3 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
WO2004048521A3 (en) Composition and method for treating lupus nephritis
AU4100199A (en) Compositions and methods for enhancing protein anabolism and detoxification
MXPA03006218A (en) Type 2 ctokine receptor and nucleic acids encoding same.
AU3711597A (en) A novel galanin receptor
EP0931834A3 (en) Echinocandin binding domain of 1,3-Beta-glucan synthase
WO2003046160A3 (en) Methods of increasing protein expression levels
WO2000024771A3 (en) Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
WO1998024896A3 (en) Muteins of obese protein
WO2000000506A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
NO992531L (en) Methods of producing recombinant protein
WO2001002429A3 (en) Angiopoietin-6 and uses thereof
EP0832972A3 (en) Cloning, expression and production of tasty peptides
WO2001023561A3 (en) Novel polynucleotides encoding proteins containing thrombospondin type 1 repeats
WO2003040345A3 (en) Type 2 cytokine receptor and nucleic acids encoding same
WO2002046417A3 (en) Adipocyte complement related protein zacrp3x2
SE9604439D0 (en) New receptor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000937682

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000937682

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09979620

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP